(3S,4S)-4-(5-chloropyridin-2-yl)-1-(oxan-4-yl)pyrrolidine-3-carboxylic acid | 1204756-72-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (3S,4S)-4-(5-chloropyridin-2-yl)-1-(oxan-4-yl)pyrrolidine-3-carboxylic acid
• CAS: 1204756-72-8
• 化学式: C₁₅H₁₉ClN₂O₃
• 分子量: 310.78
• InChiKey: WYOMSKUSJQPPMR-CHWSQXEVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  62.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Piperazine derivative
  申请人：Astellas Pharma Inc.

  公开号：US10710988B2

  公开（公告）日：2020-07-14

  [Problem] To provide a compound useful as an MC4 receptor agonist. [Means for Solution] The present inventors studied MC4 receptor agonists, and have found that a piperazine derivative has an MC4 receptor agonistic action, thereby completing the present invention. The piperazine derivative of the present invention has an MC4 receptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.

  [问题]提供一种可用作 MC4 受体激动剂的化合物。 [解决方法]本发明者对 MC4 受体激动剂进行了研究，发现一种哌嗪衍生物具有 MC4 受体激动作用，从而完成了本发明。本发明的哌嗪衍生物具有MC4受体激动作用，可用作预防或治疗膀胱和/或尿路疾病的药物，特别是膀胱活动不足、低张性膀胱、无收缩性膀胱、逼尿肌活动不足、神经源性膀胱、尿道松弛衰竭、逼尿肌-尿道外括约肌功能障碍以及良性前列腺增生症的排尿功能障碍。
• PIPERAZINE DERIVATIVE
  申请人：Astellas Pharma Inc.

  公开号：EP3489231B1

  公开（公告）日：2021-06-09
• Acylated Spiropiperidine Derivatives as Melanocortin-4 Receptor Modulators
  申请人：Jian Tianying

  公开号：US20090170863A1

  公开（公告）日：2009-07-02

  Certain novel N-acylated spiropiperidine derivatives are ligands of the human melanocortin receptor(s) and, in particular, are selective ligands of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of MC-4R, such as obesity, diabetes, nicotine addiction, alcoholism, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
• US8293900B2
  申请人：——

  公开号：US8293900B2

  公开（公告）日：2012-10-23